Tg Therapeutics (TGTX) Short term Debt (2020 - 2021)
Tg Therapeutics' (TGTX) quarterly Short term Debt came in at $975000.0 in Q4 2021, down 95.6% year-on-year from $22.2 million in Q4 2020, and down 93.91% quarter-over-quarter from $16.0 million in Q3 2021.
Tg Therapeutics (TGTX) Short term Debt (2020 - 2021) Analysis & Trends
Tg Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $975000.0 for Q4 2021.
- On a quarterly basis, Short term Debt fell 95.6% year-over-year to $975000.0 in Q4 2021; TTM through Dec 2021 was $975000.0, a 95.6% decrease from a year earlier, with the FY2021 full-year figure at $975000.0, down 95.6% from the prior year.
- Short term Debt slipped to $975000.0 in Q4 2021 per TGTX's latest filing, from $16.0 million in the prior quarter.
- Across five years, Short term Debt topped out at $30.1 million in Q1 2021 and bottomed at $975000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Tg Therapeutics | 8.88 Bn | 8.80 Bn | 171.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 975,000.00 |
| Sep 30, 2021 | 16.00 Mn |
| Jun 30, 2021 | 23.16 Mn |
| Mar 31, 2021 | 30.13 Mn |
| Dec 31, 2020 | 22.18 Mn |
| Sep 30, 2020 | 14.59 Mn |
| Jun 30, 2020 | 7.20 Mn |